The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Beam Therapeutics Inc(NASDAQ:BEAM)


Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease...
Website: http://www.beamtx.com
Founded: 2017
Full Time Employees: 166
CEO: John Evans
Sector: Healthcare
Industry: Biotechnology
Beam Therapeutics Days Payable Outstanding ttm (DPO)
Beam Therapeutics Op Cashflow Per Share ttm
Beam Therapeutics Free Cashflow Per Share ttm
Beam Therapeutics Cash Per Share ttm
Beam Therapeutics P/S ratio ttm
Beam Therapeutics (GAAP) P/E ratio ttm
Beam Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.